Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.
A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida ...
Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $ ...
In the last year, many AbbVie Inc. (NYSE:ABBV) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually ...
Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...
AbbVie Inc. (NYSE:ABBV – Free Report) – Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday ...
THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback